<DOC>
	<DOCNO>NCT01071096</DOCNO>
	<brief_summary>Twenty patient enrol 2-site , 7-month , double-blind study conduct evaluate reduction headache day attack calcitonin gene-related peptide ( CGRP ) level saliva follow treatment OnabotulinumtoxinA versus saline . Eligible patient randomize receive injection OnabotulinumtoxinA Saline Visit 1 . Following 3 month plus 1 month wash , patient receive cross-over injection Visit 5 . Patients return monthly visit exit study Visit 8 . Patients collect saliva monthly interval document daily headache diary throughout study .</brief_summary>
	<brief_title>Calcitonin Gene-related Peptide Levels Chronic Migraine</brief_title>
	<detailed_description>This double-blind study evaluate reduction number headache day follow treatment OnabotulinumtoxinA versus Saline . Additionally , CGRP level saliva correlate reduction headache attack . At Visit 1 , eligible subject randomize 1:1 receive injection OnabotulinumtoxinA Saline identical manner . Subjects collect 3 saliva sample month 7 month study : 1 collection Baseline headache level , 1 collection onset headache one degree bad Baseline level treat acute therapy , 1 collection 2 hour follow treatment . Subjects document headache headache symptom daily diary return clinic diary saliva sample monthly visit . Following 4 month ( include 1 month washout Visit 4 ) , subject return Visit 5 receive cross-over injection . Subjects randomize OnabotulinumtoxinA Visit 1 receive injection Saline . Subjects randomize saline Visit 1 receive injection OnabotulinumtoxinA . Subjects document headache headache symptom daily diary return clinic diary saliva sample monthly visit . At Visit 8 , 3 month follow re-injection Visit 5 , subject exit study .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
	<mesh_term>Salmon calcitonin</mesh_term>
	<mesh_term>Calcitonin</mesh_term>
	<criteria>must outpatient , male female , race , 18 65 year age . female childbearing potential must negative pregnancy test result Screening Visit practice reliable method contraception . A female consider childbearing potential unless post menopausal least 12 month prior administration study drug , without uterus and/or ovary surgically sterilize least 6 month prior study drug administration . Reliable method contraception : Complete abstinence intercourse 2 week prior administration investigational product , throughout study , time interval ( 5 day ) completion premature discontinuation study ; , History bilateral tubal ligation ; , Sterilization male partner ; , Implants levonorgestrel ; , Injectable progestogen ; , Oral contraceptive ( combination therapy ethinyl estradiol plus progestin ) placebo week every 13 month ; , Any intrauterine device ( IUD ) publish data show high expected failure rate le 1 % per year ( IUD 's meet criterion ) use least 30 day prior study drug administration ; , Spermicide plus mechanical barrier ( e.g. , spermicide plus male condom female diaphragm ) ; , Any barrier method ( use combination acceptable method ) use least 14 day prior study drug administration ; , Any method publish data show high expected failure rate method le 1 % per year . must history chronic migraine ( without aura ) accord criterion propose Headache Classification Committee International Headache Society ( IHS ) least 3 month prior enrollment . must able understand requirement study include maintain headache Diary , sign informed consent . must good general health determine investigator . take migraine preventive , must stable dose preventive medication least 3 month prior screen . female , pregnant , plan become pregnant study period , breast feeding , childbearing potential practicing reliable form birth control . headache disorder outside IHSdefined chronic migraine definition . evidence underlie pathology contribute headache . pathology salivary gland sialadenitis ( e.g . Sjogren 's syndrome , viral bacterial sialadenitis ) condition symptom would alter content saliva . medical condition may increase risk exposure OnabotulinumtoxinA include diagnose myasthenia gravis , EatonLambert syndrome , amyotrophic lateral sclerosis , significant disease might interfere neuromuscular function . profound atrophy weakness muscle target area injection . skin condition infection injection site . allergy sensitivity component test medication . opinion investigator , active major psychiatric depressive disorder include alcohol/drug abuse . meet International Headache Society criterion Medication Overuse opioid butalbital containing product . plan require surgery study . history poor compliance medical treatment . currently participate investigational drug study participate investigational drug study within previous 30 day screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Botox</keyword>
	<keyword>OnabotulinumtoxinA</keyword>
	<keyword>Chronic Migraine</keyword>
	<keyword>Calcitonin Gene-Related Peptide</keyword>
	<keyword>Saliva</keyword>
</DOC>